Clinical Trial Update: Persistence of Antibody Response to N. Meningitidis Group C in Children [Phase 4]

View source ↗

Summary

Phase 4 study update shows persistence of antibody responses against Neisseria meningitidis group C in children following vaccination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal Group C vaccine (Meningococcal group C vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Prevention of Meningococcal Infection | Phase 4 | Status: COMPLETED